These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 3584516)

  • 21. [Improved therapeutic response to L-dopa in Parkinson's disease, when combined with bromocriptine (author's transl)].
    Ulm G
    Nervenarzt; 1981 Feb; 52(2):116-20. PubMed ID: 7219619
    [No Abstract]   [Full Text] [Related]  

  • 22. [Bromocriptine in the treatment of Parkinson's disease].
    Sepcić J; Ledić P
    Neurologija; 1982; 30(1-4):75-81. PubMed ID: 6765062
    [No Abstract]   [Full Text] [Related]  

  • 23. [Psychosis due to the interaction of erythromycin and bromocriptine in Parkinson disease].
    Alegre M; Noé E; Martínez Lage JM
    Neurologia; 1997 Nov; 12(9):429. PubMed ID: 9471184
    [No Abstract]   [Full Text] [Related]  

  • 24. Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia.
    Aarsland D; Hutchinson M; Larsen JP
    Int J Geriatr Psychiatry; 2003 Oct; 18(10):937-41. PubMed ID: 14533126
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A "combined" levodopa test as a useful method for evaluating the efficacy of dopamine agonists: application to pergolide and bromocriptine.
    Bonnet AM; Serre I; Marconi R; Agid Y; Dubois B
    Mov Disord; 1995 Sep; 10(5):668-71. PubMed ID: 8552122
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bromocriptine in Parkinson's disease: report on 106 patients treated for up to 5 years.
    Lieberman AN; Kupersmith M; Neophytides A; Gopinathan G; Casson I; Durso R; Foo SH; Khayali M; Tartaro T; Goldstein M
    Adv Biochem Psychopharmacol; 1980; 23():245-53. PubMed ID: 7395614
    [No Abstract]   [Full Text] [Related]  

  • 27. Clinical predictors of response to Acetyl Cholinesterase Inhibitors: experience from routine clinical use in Newcastle.
    Pakrasi S; Mukaetova-Ladinska EB; McKeith IG; O'Brien JT
    Int J Geriatr Psychiatry; 2003 Oct; 18(10):879-86. PubMed ID: 14533120
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low-dosage treatment in de novo patients with Parkinson's disease: a prospective study.
    van der Drift JH
    Adv Neurol; 1987; 45():529-34. PubMed ID: 3825731
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A comparative study of bromocriptine and levodopa in Parkinson's disease.
    Duvoisin RC; Mendoza MM; Yahr MD
    Adv Biochem Psychopharmacol; 1980; 23():271-5. PubMed ID: 7395618
    [No Abstract]   [Full Text] [Related]  

  • 30. [The value of bromocriptine in the therapy of Parkinson disease].
    Castro-Caldas A
    Acta Med Port; 1981; 3(3):239-43. PubMed ID: 7325011
    [No Abstract]   [Full Text] [Related]  

  • 31. Levodopa compared with bromocriptine in the treatment of Parkinson's disease.
    Godwin-Austen RB
    Adv Biochem Psychopharmacol; 1980; 23():261-5. PubMed ID: 7395616
    [No Abstract]   [Full Text] [Related]  

  • 32. [Bromocriptine as the 1st treatment of Parkinson's disease. Long term results].
    Rascol A; Montastruc JL; Guiraud-Chaumeil B; Clanet M
    Rev Neurol (Paris); 1982; 138(5):401-8. PubMed ID: 7146724
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cognitive performances in parkinsonians before and after bromocriptine therapy.
    Piccirilli M; Piccinin GL; D'Alessandro P; Finali G; Piccolini C; Scarcella MG; Testa A
    Acta Neurol (Napoli); 1986 Jun; 8(3):167-72. PubMed ID: 3739763
    [No Abstract]   [Full Text] [Related]  

  • 34. [Bromocriptine in the treatment of patients with parkinsonism and dyskinesias induced by levodopa].
    Haas JA; Lakke JP
    Ned Tijdschr Geneeskd; 1982 Apr; 126(16):701-5. PubMed ID: 7088202
    [No Abstract]   [Full Text] [Related]  

  • 35. [Rivastigmine as adjunctive therapy in the therapeutic dilemma for the treatment of hallucinations due to Parkinson disease].
    Rovers JM; Dautzenberg PL; ter Bruggen JP
    Tijdschr Gerontol Geriatr; 2006 Jul; 37(3):117-20. PubMed ID: 16886519
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The response of "de novo" Parkinson's disease patients to bromocriptine in a "low and slow" regimen is predictive for prognosis.
    Sampaio C; Coelho T; Castro-Caldas A; Bastos-Lima A; Levy A
    J Neural Transm Suppl; 1995; 45():197-202. PubMed ID: 8748626
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low CSF GABA in Parkinsonian patients who respond poorly to therapy or suffer from the "on-off" phenomenon.
    Teychenné PF; Ziegler MG; Lake CR; Enna SJ
    Ann Neurol; 1982 Jan; 11(1):76-9. PubMed ID: 6120678
    [No Abstract]   [Full Text] [Related]  

  • 38. [Two cases of Parkinson's disease in which visual hallucinations disappeared after cataract surgery].
    Matsui H; Udaka F; Oda M; Kubori T; Nishinaka K; Kameyama M
    No To Shinkei; 2004 Apr; 56(4):351-4. PubMed ID: 15237728
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low dose bromocriptine in Parkinson disease. Effects on the clinical picture and hypophyseal hormones.
    Plascencia-Fuentes JM; Cabañas-García A; Corona-Vázquez T; Estañol-Vidal B; López-Mora M; Zárate-Treviño A
    Arch Invest Med (Mex); 1986; 17(2):135-46. PubMed ID: 3592889
    [No Abstract]   [Full Text] [Related]  

  • 40. [Dementia syndrome in depressive states. Efficacy of bromocriptine therapy].
    Julien J
    Nouv Presse Med; 1982 May; 11(21):1639. PubMed ID: 7099945
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.